Skip to main content
Premium Trial:

Request an Annual Quote

High Demand

Machines and supplies for rapid COVID-19 testing are hard to come by, according to the Wall Street Journal.

Two rapid antigen tests have been granted Emergency Use Authorization in the US — Quidel's Sofia 2 SARS Antigen FIA and Becton Dickinson's Veritor Plus SARS-CoV-2 assay. However, the Journal notes that getting supplies for these tests to doctors, nursing homes, and federal officials has been challenging. According to 360Dx, Quidel CEO Douglas Bryant has said the demand for antigen tests in particular is "unfathomable."

The Journal reports Quidel is grappling with producing enough analyzers for testing, while Becton Dickinson is wrestling with making enough tests. Both say they are ramping up production, though face supply shortages. The firms have both signed deals to provide instruments and tests to the US Department of Health and Human Services, with the government getting priority for tests and analyzers, it adds.

Katie Schafer, a pediatrician in Birmingham, Mich., tells the Journal that she ordered 1,000 COVID-19 tests to run on a Becton Dickinson analyzer, but has only received 120. "I consider ourselves lucky that we got any at all," she adds. "There's no good news coming out of the reps that sell these tests."

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.